AtaiBeckley Inc.

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address C/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119
Mailing Address C/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119
Phone 1 929 207 2670
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025 FY

$4.09M
Revenue
-$149.27M
Net Income
$292.72M
Total Assets
$70.72M
Total Liabilities
$221.87M
Stockholders' Equity
$85.30M
Cash & Equivalents
$-0.93
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 24, 2026 View on SEC
3 Initial insider ownership report March 13, 2026 View on SEC
4 Insider stock transaction report March 13, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
10-K Annual financial report March 6, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
8-K Current report of material events February 26, 2026 View on SEC
8-K Current report of material events February 19, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 17, 2026 View on SEC

Annual Reports

10-K March 6, 2026
  • AB-101, the lead compound for treatment-resistant depression, successfully completed a Phase 2b clinical trial with statistically significant improvements and a favorable safety profile.
  • A strong cash position of $285.6 million as of December 31, 2024, provides an estimated cash runway into late 2026, funding ongoing clinical trials.
View Analysis

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.